<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354599</url>
  </required_header>
  <id_info>
    <org_study_id>MT203/CPH-001</org_study_id>
    <secondary_id>U1111-1163-4003</secondary_id>
    <secondary_id>JapicCTI-142699</secondary_id>
    <nct_id>NCT02354599</nct_id>
  </id_info>
  <brief_title>Single-Dose Study of MT203</brief_title>
  <official_title>A Randomized, Single-center, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety and Pharmacokinetics of Single Subcutaneous Injection of MT203 in Healthy Adult Japanese and Caucasian Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, pharmacokinetics and pharmacodynamics of
      single subcutaneous injection of MT203 in healthy adult Japanese and Caucasian male
      participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called MT203 (Namilumab), which is a human
      immunoglobulin G1 (IgG1) mAb potently and specifically neutralizing human and macaque
      granulocyte macrophage colony stimulating factor (GM-CSF). This study will consist of Cohorts
      1 to 3 for healthy Japanese participants and Cohort 4 for healthy Caucasian participants.
      Each cohort will be comprised of 8 participants, of whom 6 participants will be randomized to
      receive MT203 and 2 participants will be randomized to receive matched placebo.

      The study population for the study will consist of 24 Japanese and 8 Caucasian healthy
      participants. Participants will be assigned to 4 cohorts which will remain undisclosed to the
      patient and study doctor during the study (unless there is an urgent medical need)::

      Cohort 1:- MT203 80 mg (6 healthy Japanese participants); Matching Placebo (2 healthy
      Japanese participants) Cohort 2:- MT203 150 mg (6 healthy Japanese participants); Matching
      Placebo (2 healthy Japanese participants) Cohort 3:- MT203 300 mg (6 healthy Japanese
      participants); Matching Placebo (2 healthy Japanese participants) Cohort 4:- MT203 150 mg (6
      healthy Caucasian participants); Matching Placebo (2 healthy Caucasian participants).

      Dosing of the Caucasian participants (Cohort 4) may occur in parallel with dosing in Japanese
      participants (Cohorts 1 to 3). Dose escalation will occur in Japanese Cohorts, independent
      from Cohort 4. The dose escalation will only occur following a review of the blinded
      safety/tolerability data up to Day 15 from the previous cohort. All participants will receive
      a single dose on Day 1, admitted from Day -1 to Day 15. Participants will return to the study
      unit for the pharmacokinetic, pharmacodynamic and safety assessment on Days 22, 29, 43, 57,
      71 and 85.

      This trial will be conducted in Japan.Overall time to participate in this trial is 85 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Vital Signs</measure>
    <time_frame>Baseline up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Body Weight</measure>
    <time_frame>Baseline up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to 12-lead Electrocardiograms (ECG)</measure>
    <time_frame>Baseline up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Lung Functioning Monitoring</measure>
    <time_frame>Baseline up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Hematology, Serum Chemistry and Urinalysis</measure>
    <time_frame>Baseline up to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC(0-inf)) of MT203</measure>
    <time_frame>Predose and at multiple time points (up to 84 days) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time 0 to Time 84 Days (AUC(0-84d)) of MT203</measure>
    <time_frame>Predose and at multiple time points (up to 84 days) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentrations (Cmax) of MT203</measure>
    <time_frame>Predose and at multiple time points (up to Day 84) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (T1/2) of MT203</measure>
    <time_frame>Predose and at multiple time points (up to 84 days) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Total Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Concentration</measure>
    <time_frame>Baseline, Hour 24, 72, 120, 168, 240, 336 hours, Day 21, 28, 42, 56, 70, 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Response for Anti MT203 Antibody</measure>
    <time_frame>Baseline, Hour 168, 336, Day 42, 84</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1: MT203 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: MT203 80 mg matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: MT203 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: MT203 150 mg matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: MT203 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: MT203 300 mg matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: MT203 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: MT203 150 mg matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT203 80 mg or matching Placebo</intervention_name>
    <description>MT203 80 mg or matching placebo injection</description>
    <arm_group_label>Cohort 1: MT203 80 mg</arm_group_label>
    <arm_group_label>Cohort 1: MT203 80 mg matching placebo</arm_group_label>
    <other_name>Namilumab</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT203 150mg or matching Placebo</intervention_name>
    <description>MT203 150mg or matching placebo injection</description>
    <arm_group_label>Cohort 2: MT203 150 mg</arm_group_label>
    <arm_group_label>Cohort 2: MT203 150 mg matching placebo</arm_group_label>
    <arm_group_label>Cohort 4: MT203 150 mg</arm_group_label>
    <arm_group_label>Cohort 4: MT203 150 mg matching placebo</arm_group_label>
    <other_name>Namilumab</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT203 300 mg or matching placebo</intervention_name>
    <description>MT203 300 mg or matching placebo injection</description>
    <arm_group_label>Cohort 3: MT203 300 mg</arm_group_label>
    <arm_group_label>Cohort 3: MT203 300 mg matching placebo</arm_group_label>
    <other_name>Namilumab</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: -

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant signs and dates a written, informed consent form and any required
             privacy authorizations prior to the initiation of any study procedures.

          3. The participant is a healthy adult male of Japanese or Caucasian (born to Caucasian
             parents and grandparents).

          4. The participant is aged 20 to 45 years, inclusive, at the time of informed consent.

          5. The participant weighs at least 50 kilogram (kg) and has a body mass index (BMI)
             between 18.5 and 25.0 kilogram per square meter (kg/m2) (for Japanese) or between 18.5
             and 30.0 kg/m2 (for Caucasian), inclusive at screening and Day-1.

          6. A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 18 weeks (126 days) after last
             dose.

        Exclusion Criteria: -

          1. The participant has received any investigational compound within 16 weeks (112 days)
             prior to the first dose of study medication.

          2. The participant has received MT203 or other anti-granulocyte-macrophage colony
             stimulating factor (GM-CSF) drugs in a previous clinical study.

          3. The participant has been vaccinated within 4 weeks (28 days) prior to the first dose
             of study medication or is scheduled to be vaccinated during the study.

          4. The participant is an immediate family member, study site employee or may consent
             under duress.

          5. The participant has uncontrolled, clinically significant neurologic, cardiovascular,
             pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, or endocrine disease
             or other abnormalities, which may impact the ability of the participant to participate
             or potentially confound the study results.

          6. History of frequent or chronic infections or herpes zoster.

          7. The participant has a history of or currently has significant pulmonary disease,
             inflammatory disease or autoimmune disease.

          8. The participant has a known hypersensitivity to any component of the formulation of
             MT203.

          9. The participant has a positive urine drug result for drugs of abuse at screening. 10.
             The participant has a history of drug abuse (defined as any illicit drug use) or a
             history of alcohol abuse within 2 years prior to the screening visit or is unwilling
             to agree to abstain from alcohol and drugs throughout the study.

        11. The participant has taken or requires excluded medications, supplements or food
        products listed in the Excluded Medications section throughout the study.

        12. The participant intends to donate sperm during the course of this study or for 18 weeks
        after the last dose of study medication.

        13. The participant has a history of cancer. 14. Presence, suspicion or history of active
        tuberculosis (TB) or latent TB infection.

        15. The participant has a positive test result for hepatitis B virus (HBV) surface antigen
        (HBsAg), hepatitis B virus antibody (HBV surface virus antibody [HBsAb]/ HBV core antibody
        [HBcAb]), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV)
        antibody/antigen at screening. However, participants who are positive for HBsAb due to HBV
        vaccination are exempt.

        16. The participant has used nicotine-containing products (including but not limited to
        cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 4 weeks
        (28 days) prior to the first dose of study medication.

        17. The participant has clinically relevant decreased lung function, example, forced
        expiratory volume in the first second (FEV1) less than (&lt;) 70 percent (%) of the predicted
        value.

        18. The participant has poor peripheral venous access. 19. The participant has undergone
        whole blood collection of at least 200 milliliter (mL) within 4 weeks (28 days) or at least
        400 mL within 12 weeks (84 days) prior to the first dose of study medication.

        20. The participant has undergone whole blood collection of at least 800 mL in total within
        52 weeks (364 days) prior to the first dose of study medication.

        21. The participant has undergone blood component collection within 2 weeks (14 days) prior
        to the start of study medication administration.

        22. Participant has an abnormal (clinically significant) electrocardiogram (ECG) at
        screening or Day 1.

        23. The participant has abnormal laboratory values at screening or Day-1 that suggest a
        clinically significant underlying disease or participant with the following laboratory
        abnormalities: Alanine transaminase (ALT) and/or aspartate transaminase (AST) greater than
        (&gt;) 1.5 times the upper limit of normal or neutrophil counts and/or monocyte counts &lt; the
        lower limit of normal.

        24. Participant who, in the opinion of the investigator, is unlikely to comply with the
        protocol or is unsuitable for the study with any other reason.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <results_first_submitted>May 12, 2016</results_first_submitted>
  <results_first_submitted_qc>May 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 20, 2016</results_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized, double-blind, placebo-controlled, single-dose subcutaneous administration study</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participant took part in the study at 1 investigative site in Japan from 25-November-2014 to 20-May-2015.</recruitment_details>
      <pre_assignment_details>Healthy Japanese and Caucasian participants were enrolled in the study as 1 of the 4 cohorts Japanese participants in Cohort 1(MT203 80 milligram [mg]), Cohort 2 (MT203 150 mg), Cohort 3 (MT203 300 mg) and Caucasian participants in Cohort 4 (MT203 150 mg) to receive MT203, or matching placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1-3: Placebo</title>
          <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: MT203 80 mg</title>
          <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2: MT203 150 mg</title>
          <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3: MT203 300 mg</title>
          <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 4: Placebo</title>
          <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 4: MT203 150 mg</title>
          <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pretreatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set (SAS) included all participants who received the study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1-3: Placebo</title>
          <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: MT203 80 mg</title>
          <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2: MT203 150 mg</title>
          <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3: MT203 300 mg</title>
          <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 4: Placebo</title>
          <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 4: MT203 150 mg</title>
          <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="2"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="8.89"/>
                    <measurement group_id="B2" value="26.0" spread="4.05"/>
                    <measurement group_id="B3" value="26.5" spread="7.79"/>
                    <measurement group_id="B4" value="24.2" spread="6.85"/>
                    <measurement group_id="B5" value="28.0" spread="7.07"/>
                    <measurement group_id="B6" value="36.0" spread="6.29"/>
                    <measurement group_id="B7" value="28.2" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Drank a few days per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drank a few days per month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never drank</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Had caffeine consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had no caffeine consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</title>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>The safety analysis set was defined as all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-3: Placebo</title>
            <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Placebo</title>
            <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</title>
          <population>The safety analysis set was defined as all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Vital Signs</title>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>The safety analysis set was defined as all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-3: Placebo</title>
            <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Placebo</title>
            <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Vital Signs</title>
          <population>The safety analysis set was defined as all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Body Weight</title>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>The safety analysis set was defined as all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-3: Placebo</title>
            <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Placebo</title>
            <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Body Weight</title>
          <population>The safety analysis set was defined as all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to 12-lead Electrocardiograms (ECG)</title>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>The safety analysis set was defined as all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-3: Placebo</title>
            <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Placebo</title>
            <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to 12-lead Electrocardiograms (ECG)</title>
          <population>The safety analysis set was defined as all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Lung Functioning Monitoring</title>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>The safety analysis set was defined as all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-3: Placebo</title>
            <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Placebo</title>
            <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Lung Functioning Monitoring</title>
          <population>The safety analysis set was defined as all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Hematology, Serum Chemistry and Urinalysis</title>
        <time_frame>Baseline up to Day 85</time_frame>
        <population>The safety analysis set was defined as all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-3: Placebo</title>
            <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Placebo</title>
            <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Hematology, Serum Chemistry and Urinalysis</title>
          <population>The safety analysis set was defined as all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC(0-inf)) of MT203</title>
        <time_frame>Predose and at multiple time points (up to 84 days) post-dose</time_frame>
        <population>The pharmacokinetic analysis set as defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC(0-inf)) of MT203</title>
          <population>The pharmacokinetic analysis set as defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacokinetic data.</population>
          <units>nanogram*day per milliliter (ng*day/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315573.3" spread="47464.44"/>
                    <measurement group_id="O2" value="575180.7" spread="126751.71"/>
                    <measurement group_id="O3" value="1238496.3" spread="222651.06"/>
                    <measurement group_id="O4" value="559689.3" spread="188835.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-Time Curve From Time 0 to Time 84 Days (AUC(0-84d)) of MT203</title>
        <time_frame>Predose and at multiple time points (up to 84 days) post-dose</time_frame>
        <population>The pharmacokinetic analysis set as defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-Time Curve From Time 0 to Time 84 Days (AUC(0-84d)) of MT203</title>
          <population>The pharmacokinetic analysis set as defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacokinetic data.</population>
          <units>ng*day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286383.2" spread="44732.15"/>
                    <measurement group_id="O2" value="502017.5" spread="116382.43"/>
                    <measurement group_id="O3" value="1106605.2" spread="207794.23"/>
                    <measurement group_id="O4" value="451596.7" spread="133571.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentrations (Cmax) of MT203</title>
        <time_frame>Predose and at multiple time points (up to Day 84) post-dose</time_frame>
        <population>The pharmacokinetic analysis set as defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentrations (Cmax) of MT203</title>
          <population>The pharmacokinetic analysis set as defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacokinetic data.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8381.3" spread="1848.65"/>
                    <measurement group_id="O2" value="15354.5" spread="5097.64"/>
                    <measurement group_id="O3" value="32580.7" spread="9061.85"/>
                    <measurement group_id="O4" value="10826.7" spread="3220.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life (T1/2) of MT203</title>
        <time_frame>Predose and at multiple time points (up to 84 days) post-dose</time_frame>
        <population>The pharmacokinetic analysis set as defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life (T1/2) of MT203</title>
          <population>The pharmacokinetic analysis set as defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacokinetic data.</population>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.75" lower_limit="22.3" upper_limit="25.7"/>
                    <measurement group_id="O2" value="26.20" lower_limit="22.6" upper_limit="43.0"/>
                    <measurement group_id="O3" value="26.15" lower_limit="22.7" upper_limit="31.1"/>
                    <measurement group_id="O4" value="32.60" lower_limit="25.2" upper_limit="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Total Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Concentration</title>
        <time_frame>Baseline, Hour 24, 72, 120, 168, 240, 336 hours, Day 21, 28, 42, 56, 70, 84</time_frame>
        <population>The pharmacodynamic analysis set was defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacodynamic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1-3: Placebo</title>
            <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: Placebo</title>
            <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Total Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Concentration</title>
          <population>The pharmacodynamic analysis set was defined as all participants who received the study medication without any major protocol deviations, and met the minimum procedure specified in the study protocol and had evaluable pharmacodynamic data.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                    <measurement group_id="O4" value="0.000" spread="0.0000"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="9.123" spread="22.3475"/>
                    <measurement group_id="O4" value="14.857" spread="23.0308"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.535" spread="20.4004"/>
                    <measurement group_id="O2" value="131.165" spread="25.2255"/>
                    <measurement group_id="O3" value="155.707" spread="37.5200"/>
                    <measurement group_id="O4" value="134.788" spread="39.9181"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.698" spread="33.8697"/>
                    <measurement group_id="O2" value="233.063" spread="46.0860"/>
                    <measurement group_id="O3" value="277.878" spread="57.0774"/>
                    <measurement group_id="O4" value="248.055" spread="79.1963"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.852" spread="48.4269"/>
                    <measurement group_id="O2" value="314.218" spread="65.0007"/>
                    <measurement group_id="O3" value="375.772" spread="72.3014"/>
                    <measurement group_id="O4" value="361.720" spread="113.4442"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387.628" spread="60.4318"/>
                    <measurement group_id="O2" value="415.098" spread="88.4198"/>
                    <measurement group_id="O3" value="489.127" spread="72.4588"/>
                    <measurement group_id="O4" value="493.835" spread="113.3446"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483.353" spread="77.2963"/>
                    <measurement group_id="O2" value="554.973" spread="122.5254"/>
                    <measurement group_id="O3" value="675.010" spread="96.1891"/>
                    <measurement group_id="O4" value="565.527" spread="137.2089"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="733.440" spread="330.8767"/>
                    <measurement group_id="O2" value="710.998" spread="202.6718"/>
                    <measurement group_id="O3" value="859.977" spread="160.9109"/>
                    <measurement group_id="O4" value="677.693" spread="194.5259"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653.467" spread="111.0059"/>
                    <measurement group_id="O2" value="758.195" spread="157.6988"/>
                    <measurement group_id="O3" value="951.438" spread="207.3810"/>
                    <measurement group_id="O4" value="781.040" spread="167.7037"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547.093" spread="81.0675"/>
                    <measurement group_id="O2" value="740.245" spread="245.6498"/>
                    <measurement group_id="O3" value="807.632" spread="193.1090"/>
                    <measurement group_id="O4" value="828.695" spread="271.3573"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>56 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431.300" spread="94.4867"/>
                    <measurement group_id="O2" value="633.093" spread="186.5863"/>
                    <measurement group_id="O3" value="758.747" spread="238.7338"/>
                    <measurement group_id="O4" value="617.653" spread="192.0337"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325.750" spread="67.8796"/>
                    <measurement group_id="O2" value="440.092" spread="126.7378"/>
                    <measurement group_id="O3" value="668.387" spread="181.7359"/>
                    <measurement group_id="O4" value="467.965" spread="173.5354"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.712" spread="44.5704"/>
                    <measurement group_id="O2" value="366.078" spread="200.2973"/>
                    <measurement group_id="O3" value="545.100" spread="151.8562"/>
                    <measurement group_id="O4" value="379.647" spread="189.7192"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Response for Anti MT203 Antibody</title>
        <time_frame>Baseline, Hour 168, 336, Day 42, 84</time_frame>
        <population>The safety analysis set was defined as all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MT203 80 mg</title>
            <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MT203 300 mg</title>
            <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: MT203 150 mg</title>
            <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Response for Anti MT203 Antibody</title>
          <population>The safety analysis set was defined as all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug on Day 1 up to Day 85</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1-3: Placebo</title>
          <description>MT203 placebo -matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: MT203 80 mg</title>
          <description>MT203 80 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: MT203 150 mg</title>
          <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3: MT203 300 mg</title>
          <description>MT203 300 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Japanese participants.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 4: Placebo</title>
          <description>MT203 placebo-matching, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 4: MT203 150 mg</title>
          <description>MT203 150 mg, injection, subcutaneously, once on Day 1 in the 15 days treatment period in Caucasian participants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Forced vital capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takedas sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

